FDA clears generic versions of Abbott's Depakote

07/30/2008 | Bloomberg

Eight drugmakers -- including Novartis AG and Teva Pharmaceutical Industries -- obtained FDA approval to market copies of Depakote DR, a delayed-release treatment for epilepsy, bipolar disorder and migraines from Abbott Laboratories. The generic treatments will have the same safety label as the brand-name version, including a "black box" warning about the risk of death from liver injury or pancreas inflammation.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN